Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the criteria required to become an NCI-designated cancer center.
Louis M. Weiner, MD
Advertisement
Articles by Louis M. Weiner, MD
Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.
Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.
Advertisement
Latest Updated Articles
Dr. Weiner on the Criteria Required to Become an NCI-Designated Cancer CenterPublished: May 10th 2019 | Updated:
Dr. Louis Weiner Discusses the T-DM1 EMILIA TrialPublished: August 27th 2012 | Updated:
Dr. Weiner on the T-DM1 Mechanism of ActionPublished: October 1st 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5